Outcome

The study highlights the significant benefits of hyperbaric oxygen therapy (HBOT) for patients with diabetes specifically those with diabetic foot ulcerations. Administering 100% oxygen at 2.4 ATA for 105 minutes over 30 sessions resulted in notable improvements in several critical health metrics including better glycaemic control as evidenced by reductions in fasting blood glucose (FBG) and haemoglobin A1c (HbA1c) levels reduced insulin resistance (HOMA-IR) and decreases in inflammation markers such as high sensitivity C-reactive protein (hs-CRP) and uric acid.

Introduction

Hyperbaric oxygen therapy (HBOT) has emerged as a promising adjunct treatment for diabetic patients especially those dealing with complications like foot ulcerations. This study investigates the impact of HBOT on key health parameters in diabetic patients focusing on glycaemic control and atherosclerosis. A total of 28 patients with Wagner grade 2-4 diabetic foot ulcers underwent 30 sessions of HBOT each involving 100% oxygen at 2.4 atmospheres absolute (ATA) for approximately 105 minutes. The results revealed significant improvements in fasting blood glucose (FBG) haemoglobin A1c (HbA1c) insulin resistance (HOMA-IR) inflammation markers (hs-CRP) uric acid mean platelet volume (MPV) complete blood count and lipid profile. These findings suggest that HBOT not only enhances glycaemic control but also reduces atherosclerosis and systemic inflammation offering a holistic benefit for diabetic patients.

Results

The study assessed the impact of hyperbaric oxygen therapy (HBOT) on diabetic patients with foot ulcerations focusing on crucial health parameters after completing 30 HBOT sessions (100% oxygen at 2.4 ATA for 105 minutes each). Significant improvements were observed in the following areas:

Fasting Blood Glucose (FBG) and Hemoglobin A1c (HbA1c): There was a notable decrease in FBG and HbA1c levels indicating better glycaemic control among participants.

Insulin Resistance (HOMA-IR): HBOT sessions led to a significant reduction in insulin resistance as reflected by improved HOMA-IR scores.

Inflammatory Markers: The study recorded substantial reductions in high sensitivity C-reactive protein (hs-CRP) and uric acid levels highlighting a decrease in systemic inflammation.

Mean Platelet Volume (MPV): A meaningful decline in MPV was observed suggesting improved platelet function and potential benefits for cardiovascular health.

Complete Blood Count: Various blood count parameters showed positive changes contributing to the overall health improvements noted in the study.

Lipid Profile: Participants exhibited enhanced lipid profiles following HBOT with improvements in key metrics that are indicative of reduced atherosclerosis risk.

The findings suggest that HBOT not only improves glycaemic control but also has significant beneficial effects on markers of inflammation and cardiovascular health in diabetic patients. This positions HBOT as a promising adjunctive therapy for managing diabetes and its complications.

Conclusion

In conclusion this study underscores the potential of hyperbaric oxygen therapy (HBOT) as an effective adjunct treatment for diabetic patients particularly those with foot ulcerations. The administration of 100% oxygen at 2.4 ATA for 105 minutes over 30 sessions led to significant improvements in crucial health metrics such as glycaemic control evidenced by reductions in fasting blood glucose (FBG) and haemoglobin A1c (HbA1c) as well as decreased insulin resistance (HOMA-IR). Additionally substantial reductions were observed in inflammation markers (hs-CRP and uric acid) mean platelet volume (MPV) and improvements in complete blood count and lipid profile. These findings suggest that HBOT not only enhances glycaemic control but also mitigates risk factors associated with atherosclerosis and systemic inflammation thus contributing to better cardiovascular health in diabetic patients.

The promising results highlight HBOT’s potential to become a valuable component in the management of diabetes and its complications paving the way for enhanced patient outcomes. However to fully elucidate the systemic benefits and mechanisms underlying these effects further large-scale randomized trials are essential. Future research should focus on confirming these preliminary findings and exploring the broader implications of HBOT in diabetes management potentially opening new avenues for treatment strategies in chronic diabetic care.